Active components of Dengzhan Shengmai ameliorate cognitive impairment by facilitating hippocampal long-term potentiation via the NMDA receptor-mediated Ca<sup>2+</sup>/CaMKII pathway

Congyu Ma; Ning Sheng; Jun Wu; Lulu Wang; Jiandong Jiang; Haibo Yu; Jinlan Zhang

doi:10.1016/j.jpha.2023.09.016

Volume 14 Issue 3

Mar. 2024

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Analysis > 2024 > 14(3): 435-438

Congyu Ma, Ning Sheng, Jun Wu, Lulu Wang, Jiandong Jiang, Haibo Yu, Jinlan Zhang. Active components of Dengzhan Shengmai ameliorate cognitive impairment by facilitating hippocampal long-term potentiation via the NMDA receptor-mediated Ca2+/CaMKII pathway[J]. Journal of Pharmaceutical Analysis, 2024, 14(3): 435-438. doi: 10.1016/j.jpha.2023.09.016

Citation:

Congyu Ma, Ning Sheng, Jun Wu, Lulu Wang, Jiandong Jiang, Haibo Yu, Jinlan Zhang. Active components of Dengzhan Shengmai ameliorate cognitive impairment by facilitating hippocampal long-term potentiation via the NMDA receptor-mediated Ca²⁺/CaMKII pathway[J]. Journal of Pharmaceutical Analysis, 2024, 14(3): 435-438. doi: 10.1016/j.jpha.2023.09.016

Citation:

Congyu Ma, Ning Sheng, Jun Wu, Lulu Wang, Jiandong Jiang, Haibo Yu, Jinlan Zhang. Active components of Dengzhan Shengmai ameliorate cognitive impairment by facilitating hippocampal long-term potentiation via the NMDA receptor-mediated Ca²⁺/CaMKII pathway[J]. Journal of Pharmaceutical Analysis, 2024, 14(3): 435-438. doi: 10.1016/j.jpha.2023.09.016

PDF( 1945 KB)

Active components of Dengzhan Shengmai ameliorate cognitive impairment by facilitating hippocampal long-term potentiation via the NMDA receptor-mediated Ca²⁺/CaMKII pathway

doi: 10.1016/j.jpha.2023.09.016

Congyu Ma^a,
Ning Sheng^a,
Jun Wu^a,
Lulu Wang^b,
Jiandong Jiang^{a,b
,
,},
Haibo Yu^{a
,
,},
Jinlan Zhang^{a
,
,}

a. State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China;
b. Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China

Funds:

This work was supported by the National Natural Science Foundation of China (Grant No.: 82204341), Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (Grant No.: 2022-I2M-2-002), and the National Key Research and Development Program of China (Grant No.: 2019YFC1708901). The authors thank ICE Bioscience Inc. for technical assistance in electrophysiological experiments. Some figure elements in Graphical abstract were generated using BioRender (https://biorender.com/).

Received Date: Jun. 28, 2023
Accepted Date: Sep. 23, 2023
Rev Recd Date: Sep. 07, 2023
Publish Date: Sep. 27, 2023

Abstract

FullText(HTML)

References(5)

References

[1]	A. Citri, R.C. Malenka, Synaptic plasticity:Multiple forms, functions, and mechanisms, Neuropsychopharmacology 33 (2008) 18-41.
[2]	H. Lu, J. Zhang, Y. Liang, et al., Network topology and machine learning analyses reveal microstructural white matter changes underlying Chinese medicine Dengzhan Shengmai treatment on patients with vascular cognitive impairment, Pharmacol. Res. 156 (2020), 104773.
[3]	N. Sheng, H. Zheng, M. Li, et al., 4,5 caffeoylquinic acid and scutellarin, identified by integrated metabolomics and proteomics approach as the active ingredients of Dengzhan Shengmai, act against chronic cerebral hypoperfusion by regulating glutamatergic and GABAergic synapses, Pharmacol. Res. 152 (2020), 104636.
[4]	X. Fan, W.Y. Jin, Y.T. Wang, The NMDA receptor complex:A multifunctional machine at the glutamatergic synapse, Front. Cell Neurosci. 8 (2014), 160.
[5]	C. Ma, N. Sheng, Y. Li, et al., A comprehensive perspective on the disposition, metabolism, and pharmacokinetics of representative multi-components of Dengzhan Shengmai in rats with chronic cerebral hypoperfusion after oral administration, J. Ethnopharmacol. 307 (2023), 116212.